Lv5
1220 积分 2021-09-15 加入
Use of pharmacokinetic versus pharmacodynamic endpoints to support human dose predictions: implications for rational drug design and early clinical development
9天前
已完结
Metabolism and Disposition of a Novel B-Cell Lymphoma-2 Inhibitor Venetoclax in Humans and Characterization of Its Unusual Metabolites
12天前
已完结
AB1034 CHARACTERIZATION OF RO7507062, A CD19-TARGETING T-CELL BISPECIFIC ANTIBODY (CD19TCB), AND DESIGN OF A PHASE 1 TRIAL IN SYSTEMIC LUPUS ERYTHEMATOSUS
14天前
已完结
Trends in the drug target landscape for autoimmune diseases
27天前
已完结
Selection of positive controls and their impact on anti-drug antibody assay performance
1个月前
已完结
Selection of positive controls and their impact on anti-drug antibody assay performance
4个月前
已关闭
Development And Validation of Cell-Based Assays For The Detection of Neutralizing Antibodies to Drug Products: A Practical Approach
4个月前
已完结
In Vitro Evaluation of Cancer Cell Immunogenicity and Antigen-Specific T-Cell Cytotoxicity by Flow Cytometry
5个月前
已关闭
P3.13D.01 Proteomic Characterization of Antibody Drug Conjugate Target Expression Profiles in Small Cell Lung Cancer (SCLC)
5个月前
已完结
TL1A inhibition for inflammatory bowel disease treatment: From inflammation to fibrosis
6个月前
已完结
皖公网安备34019202002308
